• Alert Minimally Invasive Support Device Earns CE Mark Circulite's Synergy minimally invasive circulatory support system will soon be available in Europe, now that European regulatory authorities have granted it a CE Mark, the company announced.
  • Alert EU Okays Combination Type 2 Diabetes Pill The advisory board of the European Medicines Agency has issued a "positive opinion" for a new type 2 diabetes combination product containing linagliptin and metformin.
  • Alert Abiomed's Newest Impella Pump Earns CE Mark Abiomed has announced that its Impella cVAD temporary circulatory support device has been approved for sale in Europe.
  • Rivaroxaban Gets NICE Nod in UK for AF In its final draft guidance, the UK National Institute for Clinical Excellence has recommended rivaroxaban as an option for the prevention of stroke and systemic embolism in people with atrial fibrillation.
  • Rivaroxaban Approved in Europe for AF and DVT Treatment The factor Xa oral anticoagulant rivaroxaban has been approved in the European Union for the prevention of nonvalvular AF-related stroke and systemic embolism and for the treatment of DVT.